REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

19 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

29 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

05 Dec 2024 16:05:49 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

03 Dec 2024 22:38:42 By Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

02 Dec 2024 16:31:20 By Nasdaq GlobeNewswire

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

02 Dec 2024 07:30:02 By Nasdaq GlobeNewswire

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

27 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06 Nov 2024 16:02:32 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

05 Nov 2024 09:00:30 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30 Oct 2024 16:05:23 By Nasdaq GlobeNewswire

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

25 Oct 2024 04:15:00 By Nasdaq GlobeNewswire

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

23 Oct 2024 06:00:49 By Nasdaq GlobeNewswire

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

21 Oct 2024 16:05:39 By Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07 Oct 2024 09:00:01 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

07 Aug 2024 16:05:41 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31 Jul 2024 16:05:11 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

11 Jul 2024 12:00:53 By Nasdaq GlobeNewswire

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

08 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 16:05:28 By Nasdaq GlobeNewswire